公开(公告)号：US20250066810A1

公开(公告)日：2025-02-27

申请号：US18938929

申请日：2024-11-06

Applicant: LONZA WALKERSVILLE, INC.

Inventor： Matthew HEWITT ,  Eytan ABRAHAM ,  Nicholas OSTROUT

IPC: C12N15/85 ,  A61K39/00 ,  C12N5/0783

Abstract: The present disclosure provides methods for assessing and optimizing cellular quality of a cell-based therapy that is being produced in an automated cell engineering system. The methods suitably include monitoring molecular characteristics of the cells before, during, and after the automated process to provide feedback to the process parameters. In embodiments, the cells being produced are Chimeric Antigen Receptor (CAR) T-cells.

公开(公告)号：US20250066506A1

公开(公告)日：2025-02-27

申请号：US18596319

申请日：2024-03-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Patrick VAN BERKEL ,  Kristin STRUMANE ,  Aran Frank LABRIJN ,  Joost J. NEIJSSEN ,  Joyce I. MEESTERS ,  Paul PARREN ,  Janine SCHUURMAN

IPC: C07K16/32 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  C07K16/10 ,  C07K16/28 ,  C07K16/46

Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.

公开(公告)号：US20250066505A1

公开(公告)日：2025-02-27

申请号：US18935308

申请日：2024-11-01

Applicant: Minerva Biotechnologies Corporation

Inventor： Cynthia Bamdad

IPC: C07K16/30 ,  A61K35/17 ,  A61K39/00 ,  A61K47/68 ,  G01N33/574

Abstract: The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.

公开(公告)号：US20250066487A1

公开(公告)日：2025-02-27

申请号：US18935875

申请日：2024-11-04

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung YONG ,  Ui-Jung JUNG ,  Hyejin CHUNG ,  Kyeongsu PARK ,  Wonjun SON ,  Yangsoon LEE ,  Yeunju KIM ,  Eunsil SUNG ,  Youngkwang KIM ,  Youngdon PAK ,  Minji PARK ,  Jaehyun EOM ,  Hyoju CHOI ,  Moo Young SONG ,  Na Rae LEE ,  Young Bong PARK ,  Eun-Jung LEE ,  Eun-Jung LEE

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US20250066485A1

公开(公告)日：2025-02-27

申请号：US18944958

申请日：2024-11-12

Applicant: Morphic Therapeutic, Inc.

Inventor： Adrian S. Ray ,  Monica Montesinos ,  Hua Wang ,  Min Lu ,  Fu-Yang Lin

IPC: C07K16/28 ,  A61K31/4375 ,  A61K39/00 ,  A61P9/12

Abstract: The present invention provides methods and compositions for treating a lung or heart disease and/or a disease associated with increased expression or activity of integrin α5β1, comprising administering an integrin α5β1, inhibitor to a subject. Methods of treating or preventing pulmonary hypertension, pulmonary arterial hypertension (PAH), right ventricle failure, heart failure and fibrosis are also provided herein.

公开(公告)号：US20250066484A1

公开(公告)日：2025-02-27

申请号：US18949473

申请日：2024-11-15

Applicant: ImmunityBio, Inc.

Inventor： Hans G. Klingemann ,  Laurent H. Boissel

IPC: C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C12N5/0783

Abstract: Recombinant NK cells, and particularly recombinant NK-92 cells express an anti-B7-H4 chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Most notably, CAR constructs with an intracellular domain of FcεRIγ had a significantly extended duration of expression and cytotoxicity over time. The anti-B7-H4 CAR may be expressed from RNA and DNA, preferably from a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.

公开(公告)号：US20250066482A1

公开(公告)日：2025-02-27

申请号：US18822338

申请日：2024-09-02

Applicant: Numab Therapeutics AG

Inventor： Tea GUNDE ,  Matthias BROCK ,  Christian HESS ,  Alexandre SIMONIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention relates to an isolated antibody which specifically binds human PDL1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

公开(公告)号：US20250066474A1

公开(公告)日：2025-02-27

申请号：US18946033

申请日：2024-11-13

Applicant: Janssen Biotech, Inc.

Inventor： Kyle J. Bednar ,  Naresh Kumar ,  Sanjaya Singh ,  Danlin Yang ,  Rajkumar Ganesan

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/46

Abstract: Provided herein are multispecific antibodies, that bind to CD79b and CD22, polynucleotides encoding them, vectors, host cells, methods of making and using them.

公开(公告)号：US20250066463A1

公开(公告)日：2025-02-27

申请号：US18801099

申请日：2024-08-12

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Jesper GROMADA ,  Viktoria GUSAROVA ,  Andrew J. MURPHY

IPC: C07K16/22 ,  A61K9/00 ,  A61K39/00

Abstract: The present invention provides methods for treating patients suffering from hyperlipidemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

公开(公告)号：US20250066429A1

公开(公告)日：2025-02-27

申请号：US18626126

申请日：2024-04-03

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Richard Malley ,  Yingjie Lu ,  Fan Zhang

IPC: C07K14/31 ,  A61K39/00 ,  A61K39/09 ,  A61K39/385 ,  A61K47/54 ,  A61K47/61 ,  A61P31/04

Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.